Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2018

View Archived Issues

Zinc transporter affects insulin secretion

Addicted to bile acids

Interleukin is ill-fated in late-stage atherosclerosis

Repressing neuronal attrition

In monkeys with SIV, dysbiosis doesn't equal disease progression

New Japanese trials study use of iPSC-derived dopaminergic progenitors in Parkinson's disease

Cellectar and Orano Med collaborate to develop phospholipid drug conjugates

BioLineRx begins phase I/IIa study of cancer immunotherapy AGI-134

RXI-109 shows promising results in phase I/II study in NVAMD

Shionogi's Mulpleta wins approval in the U.S.

Phase II study of Nicox's NCX-470 begins

Phase II trial shows no clinical benefit of valproic acid in autosomal dominant retinitis pigmentosa

Clover Biopharmaceuticals begins phase I study of etancercept biosimilar SCB-808

NLY-001 shows neuroprotective effect by blocking A1 astrocyte conversion in Parkinson's mice models

Azitra obtains support to further study microbiome therapeutic for Netherton syndrome

Karuna Pharmaceuticals announces plans to advance KarXT to phase II

Suven Life Sciences presents preclinical data for SUVN-M-8036

Theravance Biopharma reports 4-week results from phase II study of TD-9855 in nOH

Samumed presents characterization and preclinical results for SM-07883

Medshine Discovery presents thiazole derivatives for HSV infections

EC expands approval of Jinarc to include ADPKD patients with stage 4 CKD

Bioelectron Technology identifies new resorufin derivatives

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...